Brawn Biotech Ltd
Thu 1/10/2026,16:1:0 | BSE : BRAWN
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 24.74
Previous Close
₹ 23.57
Volume
1902
Mkt Cap ( ₹ Cr)
₹ 7.38
High
₹ 24.74
Low
₹ 24.60
52 Week High
₹ 24.74
52 Week Low
₹ 17.71
Book Value Per Share
₹ 14.98
Dividend Yield
₹ 0.00
Face Value
₹₹10.00
What's Your Call?
Collective community sentiment on Brawn Biotech Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
4 users have voted
Option Chain
Analyzes market sentiment, predicts Brawn Biotech Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Brawn Biotech - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Proceedings Of 41St AGM
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Brawn Biotech - Intimation W.R.T Letter Sent To Shareholders As Per Reg 36
-
Brawn Biotech - Reg. 34 (1) Annual Report.
-
Brawn Biotech - Notice Of 41St AGM To Be Held On 29.09.2026
-
Brawn Biotech - Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Re
-
Brawn Biotech - Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Ali
-
Brawn Biotech - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, The Un-Audited Financial Results Of T
-
Brawn Biotech has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026
-
Brawn Biotech - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Brawn Biotech Ltd stockÂ
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 4.3393 | 3.3622 | 5.065 | 6.3092 | 7.2203 |
| Liabilities | 4.3393 | 3.3622 | 5.065 | 6.3092 | 7.2203 |
| Equity | 3.0003 | 3.0003 | 3.0003 | 3.0003 | 3.0003 |
| Gross Profit | -0.3265 | -1.7731 | -1.5291 | -0.3034 | -2.0057 |
| Net Profit | 0.9406 | -1.74 | -1.247 | -0.8681 | -1.6443 |
| Cash From Operating Activities | 0.1118 | 0.0474 | -0.0256 | 0.318 | 0.1878 |
| NPM(%) | 5.54 | -12.92 | -7.56 | -3.9 | -19.07 |
| Revenue | 16.9777 | 13.4649 | 16.4946 | 22.2306 | 8.6205 |
| Expenses | 17.3042 | 15.2381 | 18.0237 | 22.534 | 10.6262 |
| ROE(%) | 20.93 | -38.72 | -27.75 | -19.31 | -36.59 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Brawn Biotech Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 851.10 | -2.37 | 21.67 | 14.04 | -26.19 | 0.58 |
| Lotus Eye Hospital and Institute Ltd | 116.45 | 0.39 | 1652.57 | 51.16 | 0.39 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 8.18 | -9.71 | 0.00 | 106.22 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 706.70 | -2.03 | 0.00 | 54.81 | -363.14 | 0.00 |
Company Info
Brawn Pharmaceuticals ltd an existing profit making company was incorporated as a private limited company in the name and style of Brawn Pharmaceuticals Pvt. Ltd. on 7th November, 1985 and was converted into a public limited company on 1st December, 1993. The company started its activities by selling pharmaceutical formulations manufactured by other companies on loan licence basis. In December, 1987 the company setup its own manufacturing facilities for manufacture of pharamaceutical formulations at W-11, Okhla Industrial Area, Phase-II, New Delhi. The plant became operational from July 1988. Since then there has been steady growth in its operations relating to formulations in tablets, capsules, and oral syrups and trading in other related items. Since the year 1989-90 the company has registered an average growth of 53% in its turnover. The company has also obtained marketing rights from few foreign companies for selling thier medical products in the domestic market. The products manufactures by the company are in the categories of Analgesics, Antibiotics, Anti Tuberculosis, Antiinflammatory, Antipyretic, Anti Malarial, B Comples and Amino Acids, Cardiovascular drugs, Antiphyscotropic drugs, Tranquilizers, Antacids, Haematinics and proteins with an installed capacity of 2000 lakhs tablets, 150 lakhs capsules and 2.00 lakhs liters of liquid syrup. The main registered branded products of the company include Bruprim, Bruhist, Brutone, Brugesic. The Company is also marketing various products viz portaneb, freewaylite, CR-50, Patented side stream nebulizers, of multinational like M\s. Medic Aid, U.K. 2002-Brawn Pharmaceuticals Ltd has informed that the Board of Directors at its meeting held on December 10, 2002 has accepted the resignation of Shri Satinder Kumar Saini as Director of the Company. 2007 -Brawn Pharmaceuticals Ltd has appointment of Shri. Manohar Lal, Shri. Mahesh Kumar Nanchal and Shri. Trilok Chand Sharma as Additional Directors of the Company w.e.f. January 10, 2007. 2011 -Company has changed its name from Brawn Pharmaceuticals Ltd. to Brawn Biotech Ltd.
Brawn Pharmaceuticals ltd an existing profit making company was incorporated as a private limited company in the name and style of Brawn Pharmaceuticals Pvt. Ltd. on 7th November, 1985 and was converted into a public limited company on 1st December, 1993. The company started its activities by selling pharmaceutical formulations manufactured by other companies on loan licence basis. In December, 1987 the company setup its own manufacturing facilities for manufacture of pharamaceutical formulations at W-11, Okhla Industrial Area, Phase-II, New Delhi. The plant became operational from July 1988. Since then there has been steady growth in its operations relating to formulations in tablets, capsules, and oral syrups and trading in other related items. Since the year 1989-90 the company has registered an average growth of 53% in its turnover. The company has also obtained marketing rights from few foreign companies for selling thier medical products in the domestic market. The products manufactures by the company are in the categories of Analgesics, Antibiotics, Anti Tuberculosis, Antiinflammatory, Antipyretic, Anti Malarial, B Comples and Amino Acids, Cardiovascular drugs, Antiphyscotropic drugs, Tranquilizers, Antacids, Haematinics and proteins with an installed capacity of 2000 lakhs tablets, 150 lakhs capsules and 2.00 lakhs liters of liquid syrup. The main registered branded products of the company include Bruprim, Bruhist, Brutone, Brugesic. The Company is also marketing various products viz portaneb, freewaylite, CR-50, Patented side stream nebulizers, of multinational like M\s. Medic Aid, U.K. 2002-Brawn Pharmaceuticals Ltd has informed that the Board of Directors at its meeting held on December 10, 2002 has accepted the resignation of Shri Satinder Kumar Saini as Director of the Company. 2007 -Brawn Pharmaceuticals Ltd has appointment of Shri. Manohar Lal, Shri. Mahesh Kumar Nanchal and Shri. Trilok Chand Sharma as Additional Directors of the Company w.e.f. January 10, 2007. 2011 -Company has changed its name from Brawn Pharmaceuticals Ltd. to Brawn Biotech Ltd.
Read More
Parent Organisation
Brawn Biotech Ltd.
Founded
07/11/1985
Managing Director
NSE Symbol
FAQ
The current price of Brawn Biotech Ltd is
The 52-week high for Brawn Biotech Ltd is
The market capitalization of Brawn Biotech Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Brawn Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Brawn Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Brawn Biotech Ltd shares.
The CEO of Brawn Biotech Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
